RPS6KB1 and liver cancer: Therefore, it indicated that therapeutic strategy by upregulating AIM2 may pave a new avenue for manipulating liver cancer, and pharmacological targeting of mTOR-S6K1 pathway may be beneficial in AIM2-deficient tumors.